KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Jazz Pharmaceuticals (JAZZ) Net Margin (2016 - 2025)

Jazz Pharmaceuticals (JAZZ) has 15 years of Net Margin data on record, last reported at 17.4% in Q4 2025.

  • For Q4 2025, Net Margin fell 16.0% year-over-year to 17.4%; the TTM value through Dec 2025 reached 22.73%, down 3653.0%, while the annual FY2025 figure was 8.33%, 2214.0% down from the prior year.
  • Net Margin reached 17.4% in Q4 2025 per JAZZ's latest filing, up from 68.7% in the prior quarter.
  • Across five years, Net Margin topped out at 20.41% in Q3 2024 and bottomed at 68.7% in Q2 2025.
  • Average Net Margin over 5 years is 0.85%, with a median of 5.93% recorded in 2022.
  • Peak YoY movement for Net Margin: skyrocketed 5249bps in 2022, then plummeted -8516bps in 2025.
  • A 5-year view of Net Margin shows it stood at 3.61% in 2021, then plummeted by -584bps to 24.69% in 2022, then skyrocketed by 138bps to 9.35% in 2023, then soared by 88bps to 17.56% in 2024, then fell by -1bps to 17.4% in 2025.
  • Per Business Quant database, its latest 3 readings for Net Margin were 17.4% in Q4 2025, 68.7% in Q2 2025, and 17.56% in Q4 2024.